… This study characterizes safety and tolerability of intravenous anifrolumab versus placebo in
… and tolerability (5, 12-14) of the recommended 300 mg dose for anifrolumab administered …

… any anifrolumab exposure (all anifrolumab) … anifrolumab 300 mg in LTE were included in
the ‘all placebo’ group before the first dose of anifrolumab in the LTE and in the ‘all anifrolumab…

… the safety and tolerability of anifrolumab, a … lupus erythematosus (SLE). Methods: In this
open-label, phase 2, dose-escalation study, patients received intravenous (IV) anifrolumab 100, …

… IIb RCT, which included open-label anifrolumab treatment for up to 3 years. The … and
tolerability of anifrolumab. A secondary objective was to evaluate the immunogenicity of anifrolumab…

… of anifrolumab 300 mg and anifrolumab 600 mg exhibited dose-proportional pharmacokinetics
in healthy volunteers. Anifrolumab … to severe systemic lupus erythematosus. Arthritis …

… The safety and tolerability of subcutaneous anifrolumab was similar to that of intravenous …
signature with sifalimumab or anifrolumab in systemic lupus erythematosus (SLE) patients in …

… An open-label extension of the MUSE trial (NCT01753193 [Citation37]) evaluated the
long-term safety and tolerability of anifrolumab 300 mg iv. over 156 weeks. Of the 218 subjects …

… The latest pharmacokinetic study of anifrolumab and systemic lupus erythematosus also
supports this conclusion (24). Ian N Bruce et al. (NCT02962960) found that subcutaneous …

… The aim of this analysis was to evaluate the safety and tolerability of anifrolumab 300 mg …
with systemic lupus erythematosus: results from the systemic lupus international collaborating …

… Consistent with the overall population, anifrolumab had an acceptable safety and tolerability
… These results are concordant with the safety and tolerability of anifrolumab in Japanese …